Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, 60% of patients with alopecia totalis showed partial hair regrowth after being treated with triamcinolone acetonide injections, with one patient achieving complete regrowth and responding well to further immunotherapy.

This chapter discusses pediatric disorders like alopecia areata and vitiligo, identifying laser and light therapies as treatment options, and highlights that the pulsed dye laser is well tolerated and effective for treating molluscum contagiosum.

This review examines existing and potential treatments for alopecia areata but does not report new clinical results, emphasizing the need for future therapies that target immune pathways or protect hair follicles from inflammation.

Minoxidil may improve hair transplants and combining treatments could help alopecia areata.

This case report documents the development of vitiligo-like lesions in a patient with autoimmune thyroiditis following the use of topical squaric acid dibutylester for alopecia.

This study suggests that combining topical squaric acid dibutylester with other therapies may improve hair regrowth in patients with alopecia areata unresponsive to topical therapy alone.

This study presents case reports of four patients with alopecia areata or alopecia universalis, highlighting varied responses to treatments like prednisone, intralesional triamcinolone, and squaric acid dibutyl ester.

This case report describes a 29-year-old woman with longstanding alopecia areata who experienced improvement in her scalp hair loss after 7 years of topical treatment with squaric acid dibutylester.

This study found that the level of expected therapeutic regrowth significantly affected hair regrowth outcomes in contact immunotherapy for alopecia areata, suggesting implications for patient education and adherence.

This review discusses the use of topical immunotherapy for severe alopecia areata and resistant viral warts, highlighting diphencyprone's advantages and the need for careful handling to avoid staff sensitisation; it reports no new clinical results.

In this study, topical azelaic acid cream 20% was observed to show acceptable efficacy for treating localized alopecia areata of the scalp, offering a potential therapeutic alternative to topical clobetasol ointment 0.05%.

This pilot study found that azelaic acid treatment for patchy alopecia areata had similar hair regrowth results as anthralin, suggesting it may be an effective topical therapy.

This review discusses common skin appendage diseases, including their pathophysiology and treatments, but does not report new results.

This review found that patients with alopecia areata may have lower levels of vitamin D, zinc, and folate, but conflicting evidence precludes definitive clinical recommendations for micronutrient supplementation.

This study found that intradermal injections of Profhilo® significantly reduced skin inflammation and pain, while altering spinal cord markers in mice with ovalbumin-induced atopic dermatitis, suggesting potential therapeutic benefits for inflammatory skin conditions involving both peripheral and central processes.

This study described the clinical characteristics of 18 pediatric patients with alopecia areata at a hospital in Denpasar from 2021 to 2023, finding equal gender distribution and hair loss as the most common symptom, with onset typically within 1–6 months.

The document says a skin condition called alopecia areata causes hair loss and stress, and is treated with strong skin creams, injections, or other therapies, but treatment success varies.

This review explores the causes and mechanisms of alopecia areata and discusses current treatments, reporting no new clinical findings.

This letter discusses immunotherapy for severe or resistant alopecia areata in a university hospital in Northern Mexico and reports no new results.

In this study, triamcinolone acetonide injections led to partial hair regrowth in 60% of alopecia totalis patients, suggesting potential benefits when followed by immunotherapy.

This review discusses the advancements in understanding and treating androgenetic alopecia and alopecia areata but reports no clinical findings; the authors emphasize the need for further research on molecular control mechanisms.

This review noted that alopecia areata is an autoimmune disease impacting hair follicles and offered insights into its complex pathogenesis involving immune responses, while highlighting ongoing research into new treatments such as Janus kinase inhibitors and other immunomodulatory drugs.

This study reports that C3H/HeJ mice and DEBR rats serve as effective models for screening potential treatments for human alopecia areata, despite certain challenges in predictability and cost.

This study used a network meta-analysis to compare alopecia areata treatments, finding that intralesional corticosteroids are most effective for mild cases, while diphenylcyclopropenone ranks highest for moderate to severe cases; further research on oral tofacitinib is needed.

This report describes a case of a woman with ophiasis-pattern alopecia areata who experienced significant hair regrowth and maintained it for 6 months after treatment with dupilumab, though she eventually relapsed.

This study found that combining 308-excimer phototherapy with intramuscular triamcinolone acetonide was effective and well tolerated for treating resistant alopecia totalis, showing a 90% overall response rate in the ten patients studied, with the best results observed in younger patients.

This study found that Diphenylcyclopropenone (DCP) was effective for treating extensive alopecia areata in Thai patients, although a high relapse rate suggests maintenance therapy might be necessary.

This study found that both superficial cryotherapy and intralesional corticosteroid injections significantly improved hair growth in patients with alopecia areata, with similar efficacy between the two treatments, establishing cryotherapy as a simple and noninvasive treatment option.

This study found that topical immunotherapy is effective for treating severe alopecia areata, though patient responses can vary, highlighting the importance of individualized treatment approaches and prolonged therapy to optimize outcomes.

This study found that liquid nitrogen cryotherapy resulted in good responses in 33% of patients with recalcitrant alopecia areata, although nearly 30% showed no response.